Theriva Biologics, Inc. (TOVX) financial statements and ratios from SEC XBRL: revenue $287000.00 (TTM), net margin -8271.4%, revenue growth -58.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $287000.00 |
| Net Margin | -8271.4% |
| Revenue Growth (YoY) | -58.8% |
| EPS Growth (YoY) | -89.1% |
| FCF Growth (YoY) | -1.4% |
| Price / Book | 0.88 |
| Price / Sales | 14.34 |
| FCF Yield | -52.0% |
| Altman Z-Score | -14.69 (distress) |
| Sector P/E (Healthcare) | 21.7 |
TOVX overview · TOVX earnings · TOVX KPIs · TOVX investor relations · TOVX ownership · TOVX peers · TOVX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.